Bliss GVS Pharma Past Earnings Performance
Past criteria checks 0/6
Bliss GVS Pharma's earnings have been declining at an average annual rate of -6.3%, while the Pharmaceuticals industry saw earnings growing at 13.5% annually. Revenues have been growing at an average rate of 2.9% per year. Bliss GVS Pharma's return on equity is 6.9%, and it has net margins of 7.9%.
Key information
-6.3%
Earnings growth rate
-6.6%
EPS growth rate
Pharmaceuticals Industry Growth | 17.5% |
Revenue growth rate | 2.9% |
Return on equity | 6.9% |
Net Margin | 7.9% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Is Bliss GVS Pharma (NSE:BLISSGVS) A Risky Investment?
Dec 15Investors Don't See Light At End Of Bliss GVS Pharma Limited's (NSE:BLISSGVS) Tunnel
Nov 23Here's Why Bliss GVS Pharma (NSE:BLISSGVS) Has Caught The Eye Of Investors
Oct 26These 4 Measures Indicate That Bliss GVS Pharma (NSE:BLISSGVS) Is Using Debt Safely
Aug 25Bliss GVS Pharma Limited's (NSE:BLISSGVS) Prospects Need A Boost To Lift Shares
Aug 07Increases to Bliss GVS Pharma Limited's (NSE:BLISSGVS) CEO Compensation Might Cool off for now
Jul 19Bliss GVS Pharma's (NSE:BLISSGVS) Dividend Will Be ₹0.50
Jul 18Bliss GVS Pharma (NSE:BLISSGVS) Is Due To Pay A Dividend Of ₹0.50
Jul 04We Think Bliss GVS Pharma's (NSE:BLISSGVS) Solid Earnings Are Understated
May 10Bliss GVS Pharma Limited's (NSE:BLISSGVS) Price Is Right But Growth Is Lacking
Apr 27Does Bliss GVS Pharma (NSE:BLISSGVS) Have A Healthy Balance Sheet?
Feb 20There Is A Reason Bliss GVS Pharma Limited's (NSE:BLISSGVS) Price Is Undemanding
Jan 26Does Bliss GVS Pharma (NSE:BLISSGVS) Have A Healthy Balance Sheet?
Jul 14Bliss GVS Pharma (NSE:BLISSGVS) Has Affirmed Its Dividend Of ₹0.50
Sep 11Bliss GVS Pharma (NSE:BLISSGVS) Is Due To Pay A Dividend Of ₹0.50
Aug 28These 4 Measures Indicate That Bliss GVS Pharma (NSE:BLISSGVS) Is Using Debt Reasonably Well
May 21Estimating The Intrinsic Value Of Bliss GVS Pharma Limited (NSE:BLISSGVS)
Apr 08A Look At Bliss GVS Pharma's (NSE:BLISSGVS) Share Price Returns
Mar 18Here's How We Evaluate Bliss GVS Pharma Limited's (NSE:BLISSGVS) Dividend
Feb 25Bliss GVS Pharma (NSE:BLISSGVS) Has A Pretty Healthy Balance Sheet
Feb 08What Type Of Shareholders Make Up Bliss GVS Pharma Limited's (NSE:BLISSGVS) Share Registry?
Jan 21Do Its Financials Have Any Role To Play In Driving Bliss GVS Pharma Limited's (NSE:BLISSGVS) Stock Up Recently?
Jan 08How Is Bliss GVS Pharma's (NSE:BLISSGVS) CEO Paid Relative To Peers?
Dec 26Did Bliss GVS Pharma's (NSE:BLISSGVS) Share Price Deserve to Gain 14%?
Dec 13Should You Use Bliss GVS Pharma's (NSE:BLISSGVS) Statutory Earnings To Analyse It?
Nov 30Revenue & Expenses Breakdown
How Bliss GVS Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 8,002 | 634 | 1,466 | 0 |
30 Jun 24 | 7,944 | 815 | 1,424 | 0 |
31 Mar 24 | 7,702 | 755 | 1,394 | 0 |
31 Dec 23 | 7,569 | 879 | 1,234 | 0 |
30 Sep 23 | 7,619 | 883 | 1,213 | 0 |
30 Jun 23 | 7,224 | 598 | 1,190 | 0 |
31 Mar 23 | 7,516 | 709 | 1,160 | 0 |
31 Dec 22 | 7,339 | 871 | 1,284 | 0 |
30 Sep 22 | 7,444 | 91 | 1,256 | 0 |
30 Jun 22 | 7,680 | 165 | 1,235 | 0 |
31 Mar 22 | 7,475 | 150 | 1,045 | 0 |
31 Dec 21 | 7,124 | 17 | 896 | 0 |
30 Sep 21 | 6,602 | 773 | 876 | 0 |
30 Jun 21 | 6,158 | 766 | 698 | 0 |
31 Mar 21 | 5,772 | 685 | 827 | 0 |
31 Dec 20 | 5,650 | 710 | 763 | 0 |
30 Sep 20 | 5,487 | 692 | 730 | 0 |
30 Jun 20 | 6,073 | 797 | 582 | 0 |
31 Mar 20 | 6,893 | 973 | 684 | 0 |
31 Dec 19 | 8,136 | 1,066 | 835 | 0 |
30 Sep 19 | 8,861 | 1,087 | 805 | 0 |
30 Jun 19 | 9,044 | 1,192 | 525 | 0 |
31 Mar 19 | 8,986 | 1,237 | 748 | 0 |
31 Dec 18 | 3,788 | 623 | 234 | 0 |
30 Sep 18 | 3,543 | 543 | 300 | 0 |
30 Jun 18 | 3,521 | 469 | 369 | 0 |
31 Mar 18 | 3,720 | 297 | 432 | 0 |
31 Dec 17 | 9,063 | 1,098 | 1,669 | 0 |
30 Sep 17 | 9,423 | 1,053 | 1,659 | 0 |
30 Jun 17 | 8,843 | 860 | 1,627 | 0 |
31 Mar 17 | 4,033 | 509 | 654 | 0 |
31 Dec 16 | 6,711 | 664 | 944 | 0 |
30 Sep 16 | 5,755 | 742 | 853 | 0 |
30 Jun 16 | 5,911 | 836 | 370 | 0 |
31 Mar 16 | 5,469 | 825 | 782 | 0 |
31 Mar 15 | 4,071 | 599 | 764 | 0 |
31 Mar 14 | 3,446 | 410 | 828 | 0 |
Quality Earnings: BLISSGVS has a large one-off loss of ₹287.4M impacting its last 12 months of financial results to 30th September, 2024.
Growing Profit Margin: BLISSGVS's current net profit margins (7.9%) are lower than last year (11.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BLISSGVS's earnings have declined by 6.3% per year over the past 5 years.
Accelerating Growth: BLISSGVS's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: BLISSGVS had negative earnings growth (-28.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (20.5%).
Return on Equity
High ROE: BLISSGVS's Return on Equity (6.9%) is considered low.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/29 06:09 |
End of Day Share Price | 2024/12/27 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Bliss GVS Pharma Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Kameswari V. S. Chavali | FirstCall Research |
Anil Burra | FirstCall Research |